Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 54 entries
Sorted by: Best Match Show Resources per page
HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).

Heliyon

Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M.
PMID: 28224137
Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb.

BACKGROUND: HIV-associated neurocognitive disorders (HAND) persist in the post-HAART era, characterized by asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorders (MND). High mobility group box 1 (HMGB1) is a non-histone chromosomal protein widely expressed in the nucleus of all...

Cite
Gougeon ML, Poirier-Beaudouin B, Durant J, et al. HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). Heliyon. 2017;3(2):e00245doi: 10.1016/j.heliyon.2017.e00245.
Gougeon, M. L., Poirier-Beaudouin, B., Durant, J., Lebrun-Frenay, C., Saïdi, H., Seffer, V., Ticchioni, M., Chanalet, S., Carsenti, H., Harvey-Langton, A., Laffon, M., Cottalorda, J., Pradier, C., Dellamonica, P., & Vassallo, M. (2017). HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). Heliyon, 3(2), e00245. https://doi.org/10.1016/j.heliyon.2017.e00245
Gougeon, Marie-Lise, et al. "HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND)." Heliyon vol. 3,2 (2017): e00245. doi: https://doi.org/10.1016/j.heliyon.2017.e00245
Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M. HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb. PMID: 28224137; PMCID: PMC5310155.
Copy Download .nbib Format: NLM
Admission of tetanus patients to the ICU: a retrospective multicentre study.

Annals of intensive care

Mahieu R, Reydel T, Maamar A, Tadié JM, Jamet A, Thille AW, Chudeau N, Huntzinger J, Grangé S, Beduneau G, Courte A, Ehrmann S, Lemarié J, Gibot S, Darmon M, Guitton C, Champey J, Schwebel C, Dellamonica J, Wipf T, Meziani F, Du Cheyron D, Kouatchet A, Lerolle N.
PMID: 29116572
Ann Intensive Care. 2017 Nov 07;7(1):112. doi: 10.1186/s13613-017-0333-y.

BACKGROUND: An extended course of tetanus (up to 6 weeks) requiring ICU admission and protracted mechanical ventilation (MV) may have a significant impact on short- and long-term survival. The subject is noteworthy and deserves to be discussed.METHODS: Twenty-two ICUs...

Cite
Mahieu R, Reydel T, Maamar A, et al. Admission of tetanus patients to the ICU: a retrospective multicentre study. Ann Intensive Care. 2017;7(1):112doi: 10.1186/s13613-017-0333-y.
Mahieu, R., Reydel, T., Maamar, A., Tadié, J. M., Jamet, A., Thille, A. W., Chudeau, N., Huntzinger, J., Grangé, S., Beduneau, G., Courte, A., Ehrmann, S., Lemarié, J., Gibot, S., Darmon, M., Guitton, C., Champey, J., Schwebel, C., Dellamonica, J., Wipf, T., Meziani, F., Du Cheyron, D., Kouatchet, A., & Lerolle, N. (2017). Admission of tetanus patients to the ICU: a retrospective multicentre study. Annals of intensive care, 7(1), 112. https://doi.org/10.1186/s13613-017-0333-y
Mahieu, Rafael, et al. "Admission of tetanus patients to the ICU: a retrospective multicentre study." Annals of intensive care vol. 7,1 (2017): 112. doi: https://doi.org/10.1186/s13613-017-0333-y
Mahieu R, Reydel T, Maamar A, Tadié JM, Jamet A, Thille AW, Chudeau N, Huntzinger J, Grangé S, Beduneau G, Courte A, Ehrmann S, Lemarié J, Gibot S, Darmon M, Guitton C, Champey J, Schwebel C, Dellamonica J, Wipf T, Meziani F, Du Cheyron D, Kouatchet A, Lerolle N. Admission of tetanus patients to the ICU: a retrospective multicentre study. Ann Intensive Care. 2017 Nov 07;7(1):112. doi: 10.1186/s13613-017-0333-y. PMID: 29116572; PMCID: PMC5676569.
Copy Download .nbib Format: NLM
Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Bernard E, Perbost I, Carles M, Michiels A, Carsenti-Etesse H, Chichmanian RM, Dunais B, Dellamonica P.
PMID: 11864154
Clin Microbiol Infect. 1997 Aug;3(4):440-446. doi: 10.1111/j.1469-0691.1997.tb00280.x.

OBJECTIVE: To evaluate the efficacy and safety of vancomycin constant-rate infusion over 24 h in the treatment of Gram-positive bone infections, METHODS: Vancomycin (40 mg/kg/day) was administered without a loading dose to 15 patients (12 male, three female) aged...

Cite
Bernard E, Perbost I, Carles M, et al. Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections. Clin Microbiol Infect. 1997;3(4):440-446doi: 10.1111/j.1469-0691.1997.tb00280.x.
Bernard, E., Perbost, I., Carles, M., Michiels, A., Carsenti-Etesse, H., Chichmanian, R. M., Dunais, B., & Dellamonica, P. (1997). Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 3(4), 440-446. https://doi.org/10.1111/j.1469-0691.1997.tb00280.x
Bernard, E., et al. "Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 3,4 (1997): 440-446. doi: https://doi.org/10.1111/j.1469-0691.1997.tb00280.x
Bernard E, Perbost I, Carles M, Michiels A, Carsenti-Etesse H, Chichmanian RM, Dunais B, Dellamonica P. Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections. Clin Microbiol Infect. 1997 Aug;3(4):440-446. doi: 10.1111/j.1469-0691.1997.tb00280.x. PMID: 11864154.
Copy Download .nbib Format: NLM
High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Clevenberg P, Durant J, Halfon P, Tran A, Manos T, Rahelinirina V, Yang G, Benzaken S, Ouzan D, Rampal P, Dellamonica P.
PMID: 11864263
Clin Microbiol Infect. 1998 Jan;4(11):644-647. doi: 10.1111/j.1469-0691.1998.tb00347.x.

OBJECTIVES: To investigate the prevalence of GB virus C (GBV-C)/hepatitis G virus (HGV) RNA and anti-E2 antibodies in different risk groups of HIV-infected patients compared to that in healthy blood donors, and to study the effects of possible interactions...

Cite
Clevenberg P, Durant J, Halfon P, et al. High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients. Clin Microbiol Infect. 1998;4(11):644-647doi: 10.1111/j.1469-0691.1998.tb00347.x.
Clevenberg, P., Durant, J., Halfon, P., Tran, A., Manos, T., Rahelinirina, V., Yang, G., Benzaken, S., Ouzan, D., Rampal, P., & Dellamonica, P. (1998). High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 4(11), 644-647. https://doi.org/10.1111/j.1469-0691.1998.tb00347.x
Clevenberg, P., et al. "High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 4,11 (1998): 644-647. doi: https://doi.org/10.1111/j.1469-0691.1998.tb00347.x
Clevenberg P, Durant J, Halfon P, Tran A, Manos T, Rahelinirina V, Yang G, Benzaken S, Ouzan D, Rampal P, Dellamonica P. High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients. Clin Microbiol Infect. 1998 Jan;4(11):644-647. doi: 10.1111/j.1469-0691.1998.tb00347.x. PMID: 11864263.
Copy Download .nbib Format: NLM
Cefuroxime axetil.

International journal of antimicrobial agents

Dellamonica P.
PMID: 18611587
Int J Antimicrob Agents. 1994 Mar;4(1):23-36. doi: 10.1016/0924-8579(94)90061-2.

Cefuroxime is the first commercially-available second-generation cephalosporine to be widely used in therapy; it is a semi-synthetic cephalosporin obtained from the 7-cephalosporanic acid nucleus of cephalosporin C. Cefuroxime axetil is the acetoxyethyl ester of cefuroxime. The majority of micro-organisms...

Cite
Dellamonica P. Cefuroxime axetil. Int J Antimicrob Agents. 1994;4(1):23-36doi: 10.1016/0924-8579(94)90061-2.
Dellamonica, P. (1994). Cefuroxime axetil. International journal of antimicrobial agents, 4(1), 23-36. https://doi.org/10.1016/0924-8579(94)90061-2
Dellamonica, P. "Cefuroxime axetil." International journal of antimicrobial agents vol. 4,1 (1994): 23-36. doi: https://doi.org/10.1016/0924-8579(94)90061-2
Dellamonica P. Cefuroxime axetil. Int J Antimicrob Agents. 1994 Mar;4(1):23-36. doi: 10.1016/0924-8579(94)90061-2. PMID: 18611587.
Copy Download .nbib Format: NLM
[Médecine et Maladies Infectieuses. Editorial].

Medecine et maladies infectieuses

Katlama C, Dellamonica P.
PMID: 20117330
Med Mal Infect. 2009 Dec;39(12):1. doi: 10.1016/S0399-077X(09)73375-X.

No abstract available.

Cite
Katlama C, Dellamonica P. Médecine et Maladies Infectieuses. Editorial. [Médecine et Maladies Infectieuses. Editorial]. Med Mal Infect. 2009;39(12):1doi: 10.1016/S0399-077X(09)73375-X.
Katlama, C., & Dellamonica, P. (2009). Médecine et Maladies Infectieuses. Editorial. [Médecine et Maladies Infectieuses. Editorial]. Medecine et maladies infectieuses, 39(12), 1. https://doi.org/10.1016/S0399-077X(09)73375-X
Katlama, C, and Dellamonica, P. "Médecine et Maladies Infectieuses. Editorial." [Médecine et Maladies Infectieuses. Editorial]. Medecine et maladies infectieuses vol. 39,12 (2009): 1. doi: https://doi.org/10.1016/S0399-077X(09)73375-X
Katlama C, Dellamonica P. Médecine et Maladies Infectieuses. Editorial. [Médecine et Maladies Infectieuses. Editorial]. Med Mal Infect. 2009 Dec;39(12):1. doi: 10.1016/S0399-077X(09)73375-X. French. PMID: 20117330.
Copy Download .nbib Format: NLM
DNA methylation impact on Fabry disease.

Clinical epigenetics

Di Risi T, Vinciguerra R, Cuomo M, Della Monica R, Riccio E, Cocozza S, Imbriaco M, Duro G, Pisani A, Chiariotti L.
PMID: 33531072
Clin Epigenetics. 2021 Feb 02;13(1):24. doi: 10.1186/s13148-021-01019-3.

BACKGROUND: Fabry disease (FD) is a rare X-linked disease caused by mutations in GLA gene with consequent lysosomal accumulation of globotriaosylceramide (Gb3). Women with FD often show highly heterogeneous symptoms that can manifest from mild to severe phenotype.MAIN BODY:...

Cite
Di Risi T, Vinciguerra R, Cuomo M, et al. DNA methylation impact on Fabry disease. Clin Epigenetics. 2021;13(1):24doi: 10.1186/s13148-021-01019-3.
Di Risi, T., Vinciguerra, R., Cuomo, M., Della Monica, R., Riccio, E., Cocozza, S., Imbriaco, M., Duro, G., Pisani, A., & Chiariotti, L. (2021). DNA methylation impact on Fabry disease. Clinical epigenetics, 13(1), 24. https://doi.org/10.1186/s13148-021-01019-3
Di Risi, Teodolinda, et al. "DNA methylation impact on Fabry disease." Clinical epigenetics vol. 13,1 (2021): 24. doi: https://doi.org/10.1186/s13148-021-01019-3
Di Risi T, Vinciguerra R, Cuomo M, Della Monica R, Riccio E, Cocozza S, Imbriaco M, Duro G, Pisani A, Chiariotti L. DNA methylation impact on Fabry disease. Clin Epigenetics. 2021 Feb 02;13(1):24. doi: 10.1186/s13148-021-01019-3. PMID: 33531072; PMCID: PMC7852133.
Copy Download .nbib Format: NLM
Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices.

Blood purification

Quenot JP, Amrouche I, Lefrant JY, Klouche K, Jaber S, Du Cheyron D, Duranteau J, Maizel J, Rondeau E, Javouhey E, Gaillot T, Robert R, Dellamonica J, Souweine B, Bohé J, Barbar SD, Sejourné C, Vinsonneau C.
PMID: 34736254
Blood Purif. 2021 Nov 04;1-10. doi: 10.1159/000518919. Epub 2021 Nov 04.

BACKGROUND: The frequency of acute kidney injury (AKI) can be as high as 50% in the intensive care unit (ICU). Despite the publication of national guidelines in France in 2015 for the use of RRT, there are no data...

Cite
Quenot JP, Amrouche I, Lefrant JY, et al. Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices. Blood Purif. 2021;1-10doi: 10.1159/000518919.
Quenot, J. P., Amrouche, I., Lefrant, J. Y., Klouche, K., Jaber, S., Du Cheyron, D., Duranteau, J., Maizel, J., Rondeau, E., Javouhey, E., Gaillot, T., Robert, R., Dellamonica, J., Souweine, B., Bohé, J., Barbar, S. D., Sejourné, C., Vinsonneau, C. (2021). Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices. Blood purification, 1-10. https://doi.org/10.1159/000518919
Quenot, Jean-Pierre, et al. "Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices." Blood purification vol. (2021): 1-10. doi: https://doi.org/10.1159/000518919
Quenot JP, Amrouche I, Lefrant JY, Klouche K, Jaber S, Du Cheyron D, Duranteau J, Maizel J, Rondeau E, Javouhey E, Gaillot T, Robert R, Dellamonica J, Souweine B, Bohé J, Barbar SD, Sejourné C, Vinsonneau C. Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices. Blood Purif. 2021 Nov 04;1-10. doi: 10.1159/000518919. Epub 2021 Nov 04. PMID: 34736254.
Copy Download .nbib Format: NLM
SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19.

Journal of clinical medicine

Perrella A, Brita M, Coletta F, Cotena S, De Marco G, Longobardi A, Sala C, Sannino D, Tomasello A, Perrella M, Russo G, Tarsitano M, Chetta M, Della Monica M, Orlando V, Coscioni E, Villani R.
PMID: 34575171
J Clin Med. 2021 Sep 08;10(18). doi: 10.3390/jcm10184061.

We hypothesized that the spread of SARS-CoV-2 in urine during a severe COVID-19 infection may be the expression of the worsening disease evolution. Therefore, the aim of this study was to verify if the COVID-19 disease severity is related...

Cite
Perrella A, Brita M, Coletta F, et al. SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19. J Clin Med. 2021;10(18)doi: 10.3390/jcm10184061.
Perrella, A., Brita, M., Coletta, F., Cotena, S., De Marco, G., Longobardi, A., Sala, C., Sannino, D., Tomasello, A., Perrella, M., Russo, G., Tarsitano, M., Chetta, M., Della Monica, M., Orlando, V., Coscioni, E., & Villani, R. (2021). SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19. Journal of clinical medicine, 10(18), . https://doi.org/10.3390/jcm10184061
Perrella, Alessandro, et al. "SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19." Journal of clinical medicine vol. 10,18 (2021). doi: https://doi.org/10.3390/jcm10184061
Perrella A, Brita M, Coletta F, Cotena S, De Marco G, Longobardi A, Sala C, Sannino D, Tomasello A, Perrella M, Russo G, Tarsitano M, Chetta M, Della Monica M, Orlando V, Coscioni E, Villani R. SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19. J Clin Med. 2021 Sep 08;10(18). doi: 10.3390/jcm10184061. PMID: 34575171; PMCID: PMC8466152.
Copy Download .nbib Format: NLM
Unlocking the Potential of Substrate-Directed CO.

ChemSusChem

Limburg B, Cristòfol À, Della Monica F, Kleij AW.
PMID: 33022846
ChemSusChem. 2020 Dec 07;13(23):6056-6065. doi: 10.1002/cssc.202002246. Epub 2020 Oct 19.

The unparalleled potential of substrate-induced reactivity modes in the catalytic conversion of carbon dioxide and alcohol or amine functionalized epoxides is discussed in relation to more conventional epoxide/CO

Cite
Limburg B, Cristòfol À, Della Monica F, et al. Unlocking the Potential of Substrate-Directed CO. ChemSusChem. 2020;13(23):6056-6065doi: 10.1002/cssc.202002246.
Limburg, B., Cristòfol, �. �., Della Monica, F., & Kleij, A. W. (2020). Unlocking the Potential of Substrate-Directed CO. ChemSusChem, 13(23), 6056-6065. https://doi.org/10.1002/cssc.202002246
Limburg, Bart, et al. "Unlocking the Potential of Substrate-Directed CO." ChemSusChem vol. 13,23 (2020): 6056-6065. doi: https://doi.org/10.1002/cssc.202002246
Limburg B, Cristòfol À, Della Monica F, Kleij AW. Unlocking the Potential of Substrate-Directed CO. ChemSusChem. 2020 Dec 07;13(23):6056-6065. doi: 10.1002/cssc.202002246. Epub 2020 Oct 19. PMID: 33022846.
Copy Download .nbib Format: NLM
Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices.

Blood purification

Quenot JP, Amrouche I, Lefrant JY, Klouche K, Jaber S, Du Cheyron D, Duranteau J, Maizel J, Rondeau E, Javouhey E, Gaillot T, Robert R, Dellamonica J, Souweine B, Bohé J, Barbar SD, Sejourné C, Vinsonneau C.
PMID: 34736254
Blood Purif. 2021 Nov 04;1-10. doi: 10.1159/000518919. Epub 2021 Nov 04.

BACKGROUND: The frequency of acute kidney injury (AKI) can be as high as 50% in the intensive care unit (ICU). Despite the publication of national guidelines in France in 2015 for the use of RRT, there are no data...

Cite
Quenot JP, Amrouche I, Lefrant JY, et al. Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices. Blood Purif. 2021;1-10doi: 10.1159/000518919.
Quenot, J. P., Amrouche, I., Lefrant, J. Y., Klouche, K., Jaber, S., Du Cheyron, D., Duranteau, J., Maizel, J., Rondeau, E., Javouhey, E., Gaillot, T., Robert, R., Dellamonica, J., Souweine, B., Bohé, J., Barbar, S. D., Sejourné, C., Vinsonneau, C. (2021). Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices. Blood purification, 1-10. https://doi.org/10.1159/000518919
Quenot, Jean-Pierre, et al. "Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices." Blood purification vol. (2021): 1-10. doi: https://doi.org/10.1159/000518919
Quenot JP, Amrouche I, Lefrant JY, Klouche K, Jaber S, Du Cheyron D, Duranteau J, Maizel J, Rondeau E, Javouhey E, Gaillot T, Robert R, Dellamonica J, Souweine B, Bohé J, Barbar SD, Sejourné C, Vinsonneau C. Renal Replacement Therapy for Acute Kidney Injury in French Intensive Care Units: A Nationwide Survey of Practices. Blood Purif. 2021 Nov 04;1-10. doi: 10.1159/000518919. Epub 2021 Nov 04. PMID: 34736254.
Copy Download .nbib Format: NLM
Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.

Cancers

Serpico AF, D'Alterio G, Vetrei C, Della Monica R, Nardella L, Visconti R, Grieco D.
PMID: 31200459
Cancers (Basel). 2019 Jun 13;11(6). doi: 10.3390/cancers11060819.

Wee1 kinase is an inhibitor of cyclin-dependent kinase (cdk)s, crucial cell cycle progression drivers. By phosphorylating cdk1 at tyrosine 15, Wee1 inhibits activation of cyclin B-cdk1 (Cdk1), preventing cells from entering mitosis with incompletely replicated or damaged DNA. Thus,...

Cite
Serpico AF, D'Alterio G, Vetrei C, et al. Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations. Cancers (Basel). 2019;11(6)doi: 10.3390/cancers11060819.
Serpico, A. F., D'Alterio, G., Vetrei, C., Della Monica, R., Nardella, L., Visconti, R., & Grieco, D. (2019). Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations. Cancers, 11(6), . https://doi.org/10.3390/cancers11060819
Serpico, Angela Flavia, et al. "Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations." Cancers vol. 11,6 (2019). doi: https://doi.org/10.3390/cancers11060819
Serpico AF, D'Alterio G, Vetrei C, Della Monica R, Nardella L, Visconti R, Grieco D. Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations. Cancers (Basel). 2019 Jun 13;11(6). doi: 10.3390/cancers11060819. PMID: 31200459; PMCID: PMC6627824.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 54 entries